Skip to content

Optimal treatment for a potentially life threatening infection called scrub typhus

Intravenous Treatment for Scrub Typhus - INTREST

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015159
Enrollment
1509
Registered
2018-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A753- Typhus fever due to Rickettsia tsutsugamushi Health Condition 2: A753- Typhus fever due to Rickettsia tsutsugamushi Health Condition 3: A753- Typhus fever due to Rickettsia tsutsugamushi

Interventions

Intervention1: IV Azithromycin: Day 1,Dose 1( Infusion 1):Azithro 500mg in 250ml NS over 1 hr Day 1, Dose1 ( Infusion 2):Polybion in 250ml NS over 2 hrs Day 1, Dose 2 ( Infusion 1):Azithro 500mg In

Sponsors

Christian Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All of the following criteria must be met: • Age =15 years old presenting with fever • Scrub typhus rapid test (RDT) positivity and/or presence of an eschar • Severe scrub typhus as per the criteria A or requiring IV treatment as decided by the attending physician • Willingness to participate in the study and written informed consent obtained from the patient / the patient’s parent(s), guardian(s) or representative(s) where necessary

Exclusion criteria

Exclusion criteria: The participant may not enter the study if ANY of the following apply: 1.Pregnancy or breastfeeding 2.Current tuberculosis (rifampicin has activity against O. tsutsugamushi) 3.Documented HIV infection, long term use of steroids, chemotherapy, other immunosuppressant therapy 4.Taking medicines that may interact with study drugs 5.Known allergy to either of the medications 6.Patients who have received azithromycin or doxycycline or chloramphenicol for more than 24 hours within 3 days prior to recruitment

Design outcomes

Primary

MeasureTime frame
Treatment success as measured as a composite of survival at 28 days, lack of persisting complications at day 7 and lack of fever at day 5Timepoint: Day28

Secondary

MeasureTime frame
Adverse events Timepoint: Up to Day 28;Measurement of serial drug levels andO. tsutsugamushi bacterial counts (by qPCR) in bloodTimepoint: Days 1, 3, 7& 10-14;Number of deaths Timepoint: Day 28

Countries

India, Lao People's Democratic Republic, Thailand

Contacts

Public ContactRoshini G

Christian Medical College

georgemvarghese@hotmail.com91-9487393015

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 9, 2026